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Objective:  To  report  on  the  use  of  chronic  myeloid  leukemia  as  a  theme  of  basic  clinical  inte-
gration for  ﬁrst  year  medical  students  to  motivate  and  enable  in-depth  understanding  of  the
basic sciences  of  the  future  physician.
Methods:  During  the  past  thirteen  years  we  have  reviewed  and  updated  the  curriculum  of
the medical  school  of  the  Universidade  Estadual  de  Campinas.  The  main  objective  of  the
new curriculum  is  to  teach  the  students  how  to  learn  to  learn.  Since  then,  a case  of  chronic
myeloid leukemia  has  been  introduced  to  ﬁrst  year  medical  students  and  discussed  in
horizontal integration  with  all  themes  taught  during  a  molecular  and  cell  biology  course.  Cell
structure and  components,  protein,  chromosomes,  gene  organization,  proliferation,  cell  cycle,
apoptosis, signaling  and  so  on  are  all  themes  approached  during  this  course.  At  the  end  of
every topic  approached,  the  students  prepare  in  advance  the  corresponding  topic  of  clinical
cases chosen  randomly  during  the  class,  which  are  then  presented  by  them.  During  the  ﬁnal
class, a  paper  regarding  mutations  in  the  abl  gene  that  cause  resistance  to  tyrosine  kinase
inhibitors is  discussed.  After  each  class,  three  tests  are  solved  in  an  interactive  evaluation.
Results: The  course  has  been  successful  since  its  beginning,  13  years  ago.  Great  motivation  of
those who  participated  in  the  course  was  observed.  There  were  less  than  20%  absences  in  the
classes. At  least  three  (and  as  many  as  nine)  students  every  year  were  interested  in  starting
research training  in  the  ﬁeld  of  hematology.  At  the  end  of  each  class,  an  interactive  evaluation
was performed  and  more  than  70%  of  the  answers  were  correct  in  each  evaluation.  Moreover,
for the  ﬁnal  evaluation,  the  students  summarized,  in  a  written  report,  the  molecular  and
therapeutic  basis  of  chronic  myeloid  leukemia,  with  scores  ranging  from  0  to  10.  Considering
all 13  years,  a  median  of  78%  of  the  class  scored  above  5  (min  74%–max  85%),  and  a  median
of 67%  scored  above  7.
Conclusion:  Chronic  myeloid  leukemia  is  an  excellent  example  of  a  disease  that  can  be  used
for clinical  basic  integration  as  this  disorder  involves  well  known  protein,  cytogenetic  and  cell
function abnormalities,  has  well-deﬁned  diagnostic  strategies  and  a  target  oriented  therapy.© 2014  Associac¸ão  Bras
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Introduction
The Faculty of Medical Sciences of the Universidade Estadual
de Campinas (UNICAMP) is considered one of the best med-
ical schools in Brazil and in Latin America. Located in São
Paulo state, in Campinas, a city of one million inhabitants
and center of a technological area comparable to the Silicon
Valley in California, the school enrolls 110 students from at
least 10 000 candidates every year from all over the country.
Thus the selection process is difﬁcult; the exams are very rig-
orous, and consist of approximately one week of evaluations
of chemistry, physics, biology, maths, Portuguese, literature,
history, geography and English.
The undergraduate medical course is nominally six years
long with the ﬁrst and second years being pre-clinical and
years ﬁve and six are trainee intern years.
Since the creation of the medical school 45 years ago,
the ﬁrst year curriculum comprises biochemistry, histology,
embryology and anatomy. The courses are based on lectures,
laboratory classes and examinations. During the past thirteen
years we  have reviewed and updated the curriculum to revi-
talize the course. The main objective of the new curriculum
was to teach the students how to learn to learn. Horizontal
and vertical integration are one focus of the new curriculum
as is the integration of basic and clinical courses.
In the new curriculum, the module ‘The Cell’ is introduced
during the ﬁrst eight weeks of the course. The module is given
in 168 h with 75% in class studies under teacher guidance and
laboratory activities, including bioinformatics, and less than
25% reserved for lectures. We  would like to report the strategy
used to apply the module ‘The Cell’ in order to maintain the
principles of the new curriculum and motivate students.
The objective of this paper is to report on the use of
chronic myeloid leukemia as a theme of basic clinical inte-
gration for ﬁrst year medical students to motivate and enable
in-depth understanding of the basic sciences of the future
physician.
Method
Chronic myeloid leukemia is a disease of the hematopoietic
stem cells, which acquire a reciprocal translocation between
chromosomes 9 and 22 (Philadelphia chromosome). This
translocation leads to a juxtaposition of the BCR gene to the
ABL gene. The ABL gene is a proto-oncogene. This juxtapo-
sition determines the activation of ABL, a tyrosine kinase
involved in the intracellular signaling which culminates in
increased proliferation and reduced apoptosis of the abnormal
clone.1,2
(1) On the ﬁrst day of this module, 1 h is reserved for
the students to interview a patient, cured of chronic myeloid
leukemia after being submitted to bone marrow transplanta-
tion.
The students have an opportunity to hear the patient,
personal and family information, the complaints which cul-
minated in going to the doctor, and the patient’s feelings
regarding the diagnosis and the evolution of the disorder
before and after the bone marrow transplantation.r. 2 0 1 5;3 7(1):63–66
A PowerPoint presentation is then shown summarizing the
epidemiology, clinical characteristics, etiologic factors of this
disease and ﬁnally, a blood smear of the patient at diagnosis
and of a normal person is shown and the signiﬁcant differ-
ences in the numbers of white cells and platelets is discussed.
This increased amount of cells is then correlated with spleen
growth which the patients had mentioned as the initial symp-
tom, during the interview.
Then, the students are given the address of the page con-
taining the clinical case on the Internet so that they can
prepare themselves for the next classes. The Internet page
includes descriptions of techniques emphasizing recently
acquired basic knowledge, and videos showing the separa-
tion of proteins, Western blot test, chromosome analysis by
standard karyotyping and in situ ﬂuorescence hybridization
(FISH), polymerase chain reaction (PCR), RNA quantiﬁcation
by reverse transcription PCR (RT-PCR), stem cell separation and
growth, and colony formation.
At the end of each basic theme, the clinical case is pre-
sented by randomly chosen students coordinated by the
teacher as follows.
(2) During the presentation of the protein theme, the stu-
dents discuss the basis of the western blot technique that
identiﬁed an abnormal band in the patient. A picture of the
Western blot results is used as an example. Only the abnor-
mal  band, present in the patient and absent in the control, is
shown.
But why does the patient present this abnormal band? The
answer to that question arises during the course.
The Western blot technique is also described and stu-
dents watch a video showing the procedure used to make
polyacrylamide gel, the application of the sample in the
gel, the migration of the proteins in the gel, the veriﬁcation
of these proteins using Coomassie blue stain, the transfer-
ence of these proteins to nitrocellulose membrane and the
revelation of these proteins using a speciﬁc antibody and a sec-
ondary antibody. Both, the video (approximately 15 min long)
and a brief description of the technique are available on the
internet.
(3) During the classes concerning chromosomes, gene
organization and transcription, the students discuss the cyto-
genetics of patients with the Philadelphia chromosome. The
traditional cytogenetics and FISH of the patient, as well as the
procedure to perform these techniques are available in the
Internet site.
At this point we discuss the relationship between the
abnormal band (previously showed) and this translocation.
The students discuss the genes that are involved in the
translocation and the relationship between these genes and
the abnormal protein.
The implication of this translocation at the RNA level
and the usefulness of this knowledge in the diagnosis of
the translocation are also studied. RT-PCR, used to demon-
strate the BCR-ABL transcript, and the importance of RT-PCR
to follow up patients after bone marrow transplantation are
discussed. RT-PCR products, before and after bone marrow
transplantation, are shown. Finally, students are able to asso-
ciate the abnormal protein to the cytogenetics and RT-PCR.
(4) During the presentation of the topic on signal transduc-
tion and the tyrosine kinase pathways, students discuss the
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ole of ABL in signal transduction, the BCR-ABL hyperphos-
horylation and its involvement in the signaling pathways,
eading to an abnormal proliferation, apoptosis and cell adhe-
ion. The relationship between ABL and BCR-ABL Western
lots using the anti-phosphotyrosine antibody is explored.
At this point we  revise all themes discussed and then
ecide upon the diagnosis.
But what should the patient’s treatment be? An alternative,
n case there is a compatible donor, could be a bone marrow
ransplantation.
(5) How precursor cells are obtained is discussed in the
hapter on cell proliferation using a video showing an aphere-
is donor selected for bone marrow transplantation. The cells
re then cultivated in vitro in order to demonstrate that there
re precursor cells capable of proliferation in response to stim-
lation using growth factors. Methylcellulose plate precursor
olonies (BFU-E and CFU-GM) are shown, and the procedure
nd principle of the method are explained. The proteins
nvolved in the cell cycle are described.
(6) How a normal hematopoietic cell is capable of differ-
ntiating by means of a speciﬁc stimulation is demonstrated
n the chapter on cell differentiation. The differentiation of
ematopoietic cells after the addition of erythropoietin in
 two-phase liquid culture of mononuclear cells obtained
rom peripheral blood from the bone marrow donor is shown.
t this point, humoral and cellular components involved in
ematopoietic cell differentiation are described.
(7) Apoptosis of normal hematopoietic cells of a patient
ith leukemia is presented in the chapter on apoptosis using
hotographs of the cells stained using hematoxylin–eosin.
poptosis of leukemic cells is delayed. The inﬂuence of the
CR-ABL protein on the regulation of the proteins of the Bcl-2
amily and its anti-apoptotic action is mentioned.
However, the ﬁrst line treatment for chronic myeloid
eukemia is not bone marrow transplantation but an oral tyro-
ine kinase inhibitor.
(8) Thus, students discuss the development of chemicals
hich modify the structure of proteins and that are capa-
le of inhibiting the functions of these proteins. The drug
matinib, as well as other tyrosine kinase inhibitors, is men-
ioned. These drugs dephosphorylate the tyrosine of the ABL
rotein and inhibit the deleterious function of the abnormal
rotein. A ﬁgure demonstrating this function is available in
he internet site. The tertiary structure of the abl gene and
he pocket with the imatinib chemical is explored. The stu-
ents have the opportunity to read layman articles on the
mpact of the discovery of imatinib in the treatment of chronic
yeloid leukemia. The aim of this last item is to demon-
trate how all the knowledge they have acquired in the basic
ourse has importance in the development of therapeutic
trategies.
(9) On the last day of the course, the students discuss a
aper, which they have previously read, published in Blood.3
he article shows in vitro analysis of cell lines transformed
ith constructs of ABL mutations, which are present in
atients resistant to imatinib treatment. The aim of this
xercise is to review what was taught during the course, to
onsolidate the knowledge acquired and to show students
ow to analyze a paper and be up to date in the ﬁeld. It is also
mportant to analyze mutations in the secondary and tertiary
12 0 1 5;3 7(1):63–66 65
structure of the ABL protein which block the binding of the
tyrosine kinase inhibitor.
Results
The course has been successful since the very beginning, 13
years ago. Students who participated in the course had great
motivation and all were very enthusiastic. Less than 20% of
the students were absent from classes and at least three (and
as many  as nine) students every year were interested in start-
ing research training in the ﬁeld of hematology. At the end
of each class, an interactive evaluation was performed and
more than 70% of the answers were correct at each evaluation.
Moreover, for their ﬁnal evaluation, the students summarize
in a written report, the molecular and therapeutic bases of
chronic myeloid leukemia. Considering all 13 years, a median
of 78% of the class scored above 5 (min 74%–max 85%), and a
median of 67% scored above 7.
Discussion
The aim of ‘The Cell’ course is to provide a basis to under-
stand the main aspects of normal and abnormal molecular
and cellular functioning of different systems.
The clinical case, approached during the entire course,
provides the student with the opportunity to acquire basic
and up-to-date knowledge regarding cell structure and func-
tion. Using chronic myeloid leukemia as an integration theme,
students learn about cell dynamics, including structural and
biochemical aspects of cell components, such as proteins,
carbohydrates and lipids, biomembranes and organelles,
receptors and signal transduction, chromatin and chromo-
somes, gene regulation, proliferation mechanisms, migration,
adhesion, differentiation and cell death among other issues. It
was also important to prepare the student to understand the
diagnostic and therapeutic techniques which have recently
been developed or which are yet to be developed as well as
to incorporate basic scientiﬁc knowledge in order to articu-
late diagnostic, therapeutic and prognostic practice. Moreover,
the paper gives students the opportunity to analyze scientiﬁc
information relevant to professional practice.
In conclusion, chronic myeloid leukemia is an excellent
disease for clinical-basic integration as it comprises well
known protein, cytogenetic and cell function abnormalities,
has well deﬁned diagnosis strategies and a target oriented
therapeutics.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s. Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M. Chronic
myelogenous leukemia: disease biology and current and future
therapeutic strategies. Hematology Am Soc Hematol Educ
Program. 2000:90–109.
mote
2 3
Detection of BCR-ABL kinase mutations in CD34+ cells from66  rev bras hematol he
. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G,
Jamieson C, et al. Advances in the biology and therapy of
chronic myeloid leukemia: proceedings from the 6th Post-ASH
International Chronic Myeloid Leukemia and
Myeloproliferative Neoplasms Workshop. Leuk Lymphoma.
2013;54(6):1151–8.r. 2 0 1 5;3 7(1):63–66
. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, et al.chronic myelogenous leukemia patients in complete
cytogenetic remission on imatinib mesylate treatment. Blood.
2005;105(5):2093–8.
